The anticancer immune response: indispensable for therapeutic success?

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Clinical Investigation

• Publication date

  2008-06-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1172/JCI35180PMID 18523649PMCID PMC2396905
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development and dynamics of robust T-cell responses to CML under imatinib treatment.

  2008cited by this paper
• Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

  2008cited by this paper
• Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma.

  2008cited by this paper
• Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

  2007cited by this paper
• Vascular Endothelial Growth Factor-Trap Overcomes Defects in Dendritic Cell Differentiation but Does Not Improve Antigen-Specific Immune Responses

  2007cited by this paper
• Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.

  2007cited by this paper
• Calreticulin exposure dictates the immunogenicity of cancer cell death

  2007cited by this paper
• Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

  2007cited by this paper
• Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer

  2007cited by this paper
• Prognosis of AIDS-Related Systemic Non-Hodgkin Lymphoma Treated With Chemotherapy and Highly Active Antiretroviral Therapy Depends Exclusively on Tumor-Related Factors

  2007cited by this paper
• A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone

  2007cited by this paper
• Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

  2007cited by this paper
• Adaptive immunity maintains occult cancer in an equilibrium state

  2007cited by this paper
• Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis

  2007cited by this paper
• Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma.

  2007cited by this paper
• Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma

  2007cited by this paper
• Immune surveillance of tumors.

  2007cited by this paper
• Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.

  2007cited by this paper
• The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

  2007cited by this paper
• Soluble Interleukin (IL)-15Rα Is Generated by Alternative Splicing or Proteolytic Cleavage and Forms Functional Complexes with IL-15*

  2007cited by this paper
• Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma.

  2007cited by this paper
• Ecto‐calreticulin in immunogenic chemotherapy

  2007cited by this paper
• Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

  2006cited by this paper
• Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients

  2006cited by this paper
• Defeating T-cell fatigue in HIV

  2006cited by this paper
• Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

  2006cited by this paper
• Frequent antibody production against RARalpha in both APL mice and patients.

  2006cited by this paper
• Frequent antibody production against RARα in both APL mice and patients

  2006cited by this paper
• Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

  2006cited by this paper
• Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.

  2006cited by this paper
• Differences in Immune Cells Engaged in Cell-Mediated Immunity After Chemotherapy for Far Advanced Pancreatic Cancer

  2006cited by this paper
• Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy

  2006cited by this paper
• Interferons, immunity and cancer immunoediting

  2006cited by this paper
• Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites.

  2006cited by this paper
• Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer

  2006cited by this paper
• Cancer despite immunosurveillance: immunoselection and immunosubversion

  2006cited by this paper
• Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

  2006cited by this paper
• Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?

  2006cited by this paper
• A novel dendritic cell subset involved in tumor immunosurveillance

  2006cited by this paper
• Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors

  2006cited by this paper
• Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia.

  2006cited by this paper
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

  2006cited by this paper
• A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

  2006cited by this paper
• The DNA damage response, immunity and cancer.

  2006cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer

  2006cited by this paper
• 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.

  2005cited by this paper
• CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

  2005cited by this paper
• Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

  2005cited by this paper
• Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

  2005cited by this paper
• Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer

  2005cited by this paper
• The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

  2005cited by this paper
• DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

  2005cited by this paper
• Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.

  2005cited by this paper
• Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.

  2005cited by this paper
• Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy

  2005cited by this paper
• Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

  2005cited by this paper
• Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA‐A24+ HRPC patients

  2005cited by this paper
• Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide

  2005cited by this paper
• Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

  2005cited by this paper
• Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy

  2005cited by this paper
• Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions.

  2005cited by this paper
• Phase I/II Combined Chemoimmunotherapy with Carcinoembryonic Antigen–Derived HLA-A2–Restricted CAP-1 Peptide and Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Primary Metastatic Colorectal Cancer

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia

  2005cited by this paper
• Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas

  2005cited by this paper
• Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination

  2005cited by this paper
• Effector memory T cells, early metastasis, and survival in colorectal cancer.

  2005cited by this paper
• Malignancy after Transplantation

  2005cited by this paper
• Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.

  2005cited by this paper
• Combination treatment using thymosin α1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice

  2005cited by this paper
• IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A

  2005cited by this paper
• Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.

  2004cited by this paper
• Gastric medullary carcinoma, a distinct entity associated with microsatellite instability‐H, prominent intraepithelial lymphocytes and improved prognosis

  2004cited by this paper
• CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

  2004cited by this paper
• Surgical Removal of Primary Tumor Reverses Tumor-Induced Immunosuppression Despite the Presence of Metastatic Disease

  2004cited by this paper
• Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination

  2004cited by this paper
• Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation1

  2004cited by this paper
• Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo

  2004cited by this paper
• Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

  2004cited by this paper
• External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing

  2004cited by this paper
• Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.

  2004cited by this paper
• PML-RARA–targeted DNA vaccine induces protective immunity in a mouse model of leukemia

  2003cited by this paper
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

  2003cited by this paper
• Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.

  2003cited by this paper
• Androgen blockade enhances response to melanoma vaccine.

  2003cited by this paper
• Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

  2003cited by this paper
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

  2002cited by this paper
• Development of antitumor immune responses in reconstituted lymphopenic hosts.

  2002cited by this paper
• Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments

  2002cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus.

  2002cited by this paper
• Toll-like receptor 4 polymorphisms and atherogenesis.

  2002cited by this paper
• Toll-like receptor 4 polymorphisms and atherogenesis.

  2002cited by this paper
• Etoposide induction of tumor immunity in Lewis lung cancer

  2001cited by this paper
• Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.

  2001cited by this paper
• T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

  2001cited by this paper
• Spontaneous regression of merkel cell carcinoma: a comparative study of TUNEL index and tumor-infiltrating lymphocytes between spontaneous regression and non-regression group.

  2000cited by this paper
• Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo.

  2000cited by this paper
• TLR4 mutations are associated with endotoxin hyporesponsiveness in humans

  2000cited by this paper

• Predictors of postoperative recurrence in locally advanced gastric cancer patients achieving pathological complete response after neoadjuvant therapy: a matched case-control study

  2026cites this paper
• Treatment outcomes of dogs with transitional cell carcinoma

  2025cites this paper
• Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report

  2025cites this paper
• Synergistic effects of laser interstitial thermal therapy (LITT) and immunotherapy for brain tumor recurrence: A systematic review and meta-analysis.

  2025cites this paper
• Emerging Research and Future Directions on Doxorubicin: A Snapshot

  2025cites this paper
• Chitosan in cancer therapy: a dual role as a therapeutic agent and drug delivery system

  2024cites this paper
• In vitro induction of anti‑lung cancer immune response by the A549 lung cancer stem cell lysate‑sensitized dendritic cell vaccine

  2024cites this paper
• Iron Oxide Nanoparticles Inhibit Tumor Progression and Suppress Lung Metastases in Mouse Models of Breast Cancer

  2024cites this paper
• Green formulation of iron nanoparticles by plant extract induces apoptosis via P53 and STAT3 signaling pathways in prostate cancer cells

  2024cites this paper
• Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective

  2024cites this paper
• Predictive value of stromal tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant chemotherapy: A meta-analysis

  2024cites this paper
• Biomaterials in Drug Delivery: Advancements in Cancer and Diverse Therapies—Review

  2024cites this paper
• Effect of combination of Beta Glucan and Lactobacillus rhamnosus HerizI on white blood cell counts and serum levels of IL-4 and IL-12 in women with breast cancer undergoing chemotherapy: A randomized double-blind placebo-controlled clinical trial.

  2024cites this paper
• Epithelial Ovarian Cancer: Microenvironment and Immunecheck Point Inhibitors

  2023cites this paper
• The role of switch maintenance therapy in urothelial cancers

  2023cites this paper
• Immunogenic chemotherapy: great potential for improving response rates

  2023cites this paper
• Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models

  2023cites this paper
• Expression of programmed death ligand-1 (PD-L1) and tumor infiltrating lymphocytes (TILs) in breast carcinoma and their clinical significance

  2023cites this paper
• The role of immune subtyping in glioma mRNA vaccine development.

  2023cites this paper
• Marine natural product lepadin A as a novel inducer of immunogenic cell death via CD91-dependent pathway

  2023cites this paper
• A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells

  2023cites this paper
• The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation

  2023cites this paper
• Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes

  2023cites this paper
• Immunotargeting of Cancer Stem Cells

  2023cites this paper
• Mast cells in colorectal cancer tumour progression, angiogenesis, and lymphangiogenesis

  2023influential citation
• Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.

  2023cites this paper
• Immunogenic cell stress and death in the treatment of cancer.

  2023cites this paper
• Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses

  2023cites this paper
• Conventional type 1 dendritic cells (cDC1) in cancer immunity

  2023cites this paper
• Research Progress on the Mechanism of Anti-Tumor Immune Response Induced by TTFields

  2023cites this paper
• Predicting Response to Anthracyclines in Ovarian Cancer

  2022cites this paper
• Growth Inhibition of Retinoblastoma Cell Line by Exosome-Mediated Transfer of miR-142-3p

  2022cites this paper
• Embracing simplicity in biomaterials design

  2022cites this paper
• Dissecting Immunotherapy Strategies for Small Cell Lung Cancer: Antibodies, Ionizing Radiation and CAR-T

  2022cites this paper
• Canine Apocrine Gland Anal Sac Adenocarcinoma: A Review.

  2022cites this paper
• Expression of NOTCH1, NOTCH4, HLA-DMA and HLA-DRA is synergistically associated with T cell exclusion, immune checkpoint blockade efficacy and recurrence risk in ER-negative breast cancer

  2022cites this paper
• Metronomic Chemotherapy in Prostate Cancer

  2022cites this paper
• A Target Animal Effectiveness Study on Adjuvant Peptide-Based Vaccination in Dogs with Non-Metastatic Appendicular Osteosarcoma Undergoing Amputation and Chemotherapy

  2022cites this paper
• Anticancer Activity of Hydatid Cyst Fluid along with Antigen B on Tumors Induced by 4T1 Breast Cancer Cell in a BALB/c Mice Model

  2022cites this paper
• Moxibustion attenuates inflammation in intestinal mucosal by regulating RAGE-mediated TLR4-NF-κBp65 signaling pathway in vivo and in vitro.

  2022cites this paper
• The importance of being CAFs (in cancer resistance to targeted therapies)

  2022cites this paper
• LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer

  2022cites this paper
• SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival

  2022cites this paper
• Switch Maintenance Therapy for Metastatic Urothelial Carcinoma

  2022cites this paper
• Progress of CTLA-4 and PD-1 Immune Checkpoint Inhibitors in Treatment for Colorectal Cancer

  2022cites this paper
• Thyroid Dysfunction in Non‐Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta‐Analysis

  2022cites this paper
• Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance

  2022cites this paper
• Metabolic Homeostasis‐Regulated Nanoparticles for Antibody‐Independent Cancer Radio‐Immunotherapy

  2022cites this paper
• Development and Validation of an Age-Related Gastric Cancer-Specific Immune Index

  2022cites this paper
• Role of purinergic system and vitamin D in the anti-cancer immune response.

  2021cites this paper
• Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy

  2021cites this paper
• How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review

  2021cites this paper
• An Immunosuppressive Status Classi er to Predict Recurrence and Assist in Decision Regarding Postoperative Adjuvant Treatment in Gastric Cancer

  2021cites this paper
• All‐trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down‐regulating B7‐H6 expression via c‐Myc signaling

  2021cites this paper
• Targeting the purinergic pathway in breast cancer and its therapeutic applications

  2021cites this paper
• Anticancer drugs in the aquatic ecosystem: Environmental occurrence, ecotoxicological effect and risk assessment.

  2021cites this paper
• Insights into the role of ERp57 in cancer

  2021cites this paper
• Identification of key genes and microRNA regulatory network in development and progression of urothelial bladder carcinoma

  2021cites this paper
• The value of immunotherapy in pediatric leukemia and lymphoma

  2021cites this paper
• Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation.

  2021cites this paper
• Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study

  2021cites this paper
• Study of Bone Marrow Lymphocyte Subset in Acute Myeloid Leukemia

  2021cites this paper
• Osteosarcoma in Children: Not Only Chemotherapy

  2021cites this paper
• Maintenance avelumab in metastatic urothelial cancer patients

  2021cites this paper
• Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects

  2021cites this paper
• Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect

  2021cites this paper
• Symphony of nanomaterials and immunotherapy based on the cancer–immunity cycle

  2021cites this paper
• Novel Approaches of Dysregulating Lysosome Functions in Cancer Cells by Specific Drugs and Its Nanoformulations: A Smart Approach of Modern Therapeutics

  2021cites this paper
• Synergistic Effects of Acoustics-based Therapy and Immunotherapy in Cancer Treatment

  2021cites this paper
• Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity.

  2021cites this paper
• Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis

  2021cites this paper
• Time-Programmed Delivery of Sorafenib and Anti-CD47 Antibody via a Double-Layer-Gel Matrix for Postsurgical Treatment of Breast Cancer

  2021cites this paper
• Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models

  2021cites this paper
• Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases

  2021cites this paper
• Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

  2021cites this paper
• Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

  2021cites this paper
• Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells

  2020cites this paper
• Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations

  2020cites this paper
• Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis

  2020cites this paper
• Liver Transplantation for Pediatric Liver Cancer

  2020cites this paper
• Dendritic cell therapy in cancer treatment; the state-of-the-art.

  2020cites this paper
• PD‐1/PD‐L1‐dependent immune response in colorectal cancer

  2020cites this paper
• Immunological role and underlying mechanisms of B7-H6 in tumorigenesis.

  2020cites this paper
• The effect of nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: A randomized controlled trial.

  2020cites this paper
• CMAR_A_261828 9725..9734

  2020cites this paper
• Monitoring Cellular Immune Responses in Cancer Therapy

  2020cites this paper
• Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects

  2020cites this paper
• Immune Modulation in Lung Cancer: Current Concepts and Future Strategies

  2020cites this paper
• Toll‐like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists

  2020cites this paper
• Combination therapy: Future directions of immunotherapy in small cell lung cancer

  2020cites this paper
• Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses

  2020cites this paper
• Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo

  2020cites this paper
• ANLN Directly Interacts with RhoA to Promote Doxorubicin Resistance in Breast Cancer Cells

  2020cites this paper
• PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer

  2020cites this paper
• An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer

  2020cites this paper
• Prostate immunology: A challenging puzzle.

  2020cites this paper
• Prognostic and Predictive Value of an Immunoscore Signature in Glioblastoma Multiform

  2020cites this paper
• PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response

  2020cites this paper
• PD-1/PD-L1 axis importance and tumor microenvironment immune cells.

  2020cites this paper
• High levels of tumor-infiltrating lymphocytes showed better clinical outcomes in FOLFOX-treated gastric cancer patients.

  2020cites this paper